Stoke Therapeutics to Present at Upcoming Investor Conferences in September
03 Settembre 2024 - 2:00PM
Business Wire
Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company
dedicated to restoring protein expression by harnessing the body’s
potential with RNA medicine, today announced that management will
present at the following upcoming investor conferences:
H.C. Wainwright 26th Annual Global Investment Conference
Date: Tuesday, September 10, 2024 Time: 12:00 p.m.
ET
2024 Cantor Fitzgerald Global Healthcare Conference
Date: Tuesday, September 17, 2024 Time: 11:30 a.m.
ET
Live webcasts of each event and an archived replay of the
webcasts following each event, will be available on the Investors
& News section of Stoke’s website at
https://investor.stoketherapeutics.com/.
About Stoke Therapeutics
Stoke Therapeutics (Nasdaq: STOK), is a biotechnology company
dedicated to restoring protein expression by harnessing the body’s
potential with RNA medicine. Using Stoke’s proprietary TANGO
(Targeted Augmentation of Nuclear Gene Output) approach, Stoke is
developing antisense oligonucleotides (ASOs) to selectively restore
protein levels. Stoke’s first compound, zorevunersen (STK-001), is
in clinical testing for the treatment of Dravet syndrome, a severe
and progressive genetic epilepsy. Dravet syndrome is one of many
diseases caused by a haploinsufficiency, in which a loss of ~50% of
normal protein levels leads to disease. Stoke is pursuing the
development of STK-002 for the treatment of autosomal dominant
optic atrophy (ADOA), the most common inherited optic nerve
disorder. Stoke’s initial focus is haploinsufficiencies and
diseases of the central nervous system and the eye, although proof
of concept has been demonstrated in other organs, tissues, and
systems, supporting its belief in the broad potential for its
proprietary approach. Stoke is headquartered in Bedford,
Massachusetts with offices in Cambridge, Massachusetts. For more
information, visit https://www.stoketherapeutics.com/.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240903002278/en/
Stoke Investor Contact: Doug Snow Director,
Communications & Investor Relations IR@stoketherapeutics.com
508-642-6485
Grafico Azioni Stoke Therapeutics (NASDAQ:STOK)
Storico
Da Gen 2025 a Feb 2025
Grafico Azioni Stoke Therapeutics (NASDAQ:STOK)
Storico
Da Feb 2024 a Feb 2025